Search

BACKGROUND In this study, we assessed the role of CD200 and CD200 receptor (CD200R) in regulating CD4+T cell subsets and assessed the therapeutic efficacy of thermal ablation for liver hepatocellular carcinoma (HCC) in rats. MATERIAL AND METHODS Seventy-eight male C57BL/6 rats were randomly divided into 7 groups: a control group, a model group, a CD200FC group, an anti-CD200R1 mAb group, a thermal ablation group, a thermal ablation+CD200 FC group, and a thermal ablation+anti-CD200R1 mAb group. The levels of CD200, CD200R1, Th1, Th17, and Treg in peripheral blood were detected by flow cytometry. Immunohistochemistry was used to detect CD200, CD200R1, IFN-γ, IL-17, Foxp3 protein expression in tumor tissues. RESULTS The levels of CD200, CD200R1, Th17, and Treg were significantly increased after CD200FC treatment (p<0.05). After treatment with anti-CD200R1 mAb, the levels of CD200, CD200R1, Th17, and Treg decreased and Th1 increased. Compared with the control group, the expression of CD200, CD200R1, IL-17, and Foxp3 in the model group increased significantly, and the expression of IFN-γ decreased significantly (p<0.05). The expression of CD200, CD200R1, IL-17, and Foxp3 was significantly reduced by adding anti-CD200R1 mAb, and the expression of IFN-γ was increased (p<0.05). After the thermal ablation treatment, the proteins continued to decrease and the expression of IFN-γ continued to increase. CONCLUSIONS The CD200/CD200R pathway participates in HCC tumor growth and the expression of CD4+T cell subsets in cancer tissues. Furthermore, thermal ablation treatment inhibited cancer recurrence.

Aim: To investigate the association between the CTLA-4 promoter-1722(T/C) and 3' untranslated region CT60(G/A) polymorphisms and the risk of breast cancer in Han women of northeast China., Methods: 328 patients with breast cancer and 327 healthy people as control were genotyped for -1722 and CT60 polymorphism using polymerase chain reaction and restriction fragment length polymorphism., Results: The frequency of the G allele at the CT60 site in breast cancer patients was statistically higher than that in control(28.7% vs 23.5%, P=0.0352, OR=1.30, 95% CI=1.02-1.67). The frequency of -1722C-CT60A haplotype in control was significantly higher than that in breast cancer patients(P=0.0283, OR=0.77, 95% CI=0.97-0.61). However, the distribution of genotypes at -1722 site was not significantly different between breast cancer patients and control., Conclusion: The polymorphism of -1722T/C and CT60G/A may be related to the development of breast cancer in Han women of northern China.